NCT00532935View on ClinicalTrials.gov

MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)

PHASE3CompletedINTERVENTIONAL
Enrollment

517

Participants

Timeline

Start Date

January 26, 2008

Primary Completion Date

October 23, 2009

Study Completion Date

October 23, 2009

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

sitagliptin phosphate (+) metformin hydrochloride

sitagliptin phosphate (+) metformin hydrochloride 50/500 mg tablet bid, titrating up to sitagliptin phosphate (+) metformin hydrochloride 50/1000 mg tablet for an \~32 wk treatment period

DRUG

Comparator: pioglitazone

pioglitazone 30 mg tablet qd, titrating up to 45 mg qd for an \~32-wk treatment period.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00532935 - MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066) | Biotech Hunter | Biotech Hunter